{"commentary":{"count":27,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":16,"podcast":10,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03106987\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"OReO","nct_id":"NCT03106987","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=oreo-nct03106987. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"OReO","arms":[{"description":"Olaparib 300mg tablets administered orally twice daily continuously.","label":"Active Comparator: Olaparib","type":"EXPERIMENTAL"},{"description":"Matching placebo 300mg tablets administered orally twice daily continuously.","label":"Placebo Comparator: Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":["European Network of Gynaecological Oncological Trial Groups (ENGOT)"],"completion_date":{"date":"2022-02-17","type":"ACTUAL"},"conditions":["Epithelial Ovarian Cancer"],"enrollment":{"count":220,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Active Comparator: Olaparib tablets","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2022-10-07","lead_sponsor":"AstraZeneca","official_title":"A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2021-02-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Efficacy: Progression-free Survival (PFS)","timeFrame":"At randomization visit and at every 12 weeks (+/- 7 days) until objective radiological disease progression as determined by the investigator or other discontinuation criteria are met (assessed upto 3.8 years)"}],"references":[{"citation":"Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marme F, Lindemann K, Colombo N, Madry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Perez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A; OReO/ENGOT-ov38 investigators. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann Oncol. 2023 Dec;34(12):1152-1164. doi: 10.1016/j.annonc.2023.09.3110. Epub 2023 Oct 4.","pmid":"37797734","type":"DERIVED"}],"start_date":{"date":"2017-06-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.","url":"https://clinicaltrials.gov/study/NCT03106987"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/oreo-nct03106987"}